An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Prostate Cancer|Breast Cancer|Lung Cancer|Colorectal Cancer|Head and Neck Cancer
Interventions: BIOLOGICAL: GI-6207 [Recombinant Saccharomyces Cerevisia|DRUG: (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])
Sponsor: National Cancer Institute (NCI)